About GSK

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. 

  • £30.8bn

    turnover in 2018

  • 3

    global businesses

  • 300

    years of innovation

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people.

Pharmaceuticals

T-cells attacking a cancer cell
Immune system T-cells attacking a cancer cell

Vaccines

Herpes zoster virus of shingles
Herpes zoster virus of shingles

Consumer Healthcare

Novamin, a key technology in Sensodyne
Novamin, a key technology in Sensodyne Repair and Protect

How we do it

Everyone at GSK is focused on 3 priorities – Innovation, Performance, Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £3.9bn

    R&D investment in 2018

  • 44

    new medicines in development at Q2 2019

  • 17

    oncology assets in our pipeline at Q2 2019, which has more than doubled from 8 in the last 12 months

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

  • £30.8bn

    total turnover in 2018

  • £8.7bn

    adjusted operating profit in 2018

  • £5.7bn

    free cash flow in 2018

  • £3.9bn

    dividends paid in 2018

Trust

We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. 

  • 78%

    employee engagement score on our latest employee survey

  • £224m

    donated in 2018 to community health programmes

  • 1st

    in Access to Medicines Index since the assessment began in 2008

Key figures

Please refer to our quarterly results materials for further information on GSK’s financial performance.

Our geographies

  • £12.0bn (39%)

    US (+9% CER) sales turnover 2018

  • £8.0bn (26%)

    Europe (-1% CER) sales turnover 2018

  • £10.9bn (35%)

    International (+4% CER) sales turnover 2018